Baxter’s neuropathy, technically known as the entrapment of the first branch of the lateral plantar nerve (FBLPN) or the inferior calcaneal nerve (ICN), represents a frequently overlooked yet critical cause of chronic, recalcitrant heel pain. Often misdiagnosed as plantar fasciitis, this condition involves the compression of the nerve as it courses between the abductor hallucis muscle fascia and the medial border of the quadratus plantae muscle. Effective treatment necessitates a staged, comprehensive approach that begins with conservative non-surgical management and progresses to targeted, often minimally invasive, surgical interventions when necessary. The progression of care aims to alleviate nerve compression, reduce inflammation, and restore pain-free function to the foot, thereby providing lasting relief for a condition notoriously resistant to standard heel pain protocols.
The initial and most critical phase of treatment for Baxter’s neuropathy is conservative management, which seeks to reduce the mechanical stress and inflammation surrounding the entrapped nerve. Since the nerve entrapment is often exacerbated by underlying biomechanical faults, such as excessive foot pronation (flat feet) or a tight plantar fascia, early interventions focus on modifying causative factors. The first step involves activity modification and rest to halt the repetitive trauma that irritates the nerve, coupled with the use of cold therapy and non-steroidal anti-inflammatory drugs (NSAIDs) to manage acute inflammation and pain.
A cornerstone of conservative therapy is the use of custom-molded foot orthotics. However, unlike orthotics prescribed for plantar fasciitis, which often target longitudinal arch support, devices for Baxter’s neuropathy must be precisely crafted to offload the medial heel area where the nerve is compressed. Improperly designed orthotics can inadvertently worsen the condition by increasing pressure on the nerve, highlighting the need for a specialized prescription based on a biomechanical assessment. Supportive, well-cushioned footwear that accommodates the orthotics and avoids excessive pressure points is also paramount.
Beyond external mechanical support, physical therapy plays a vital role. Targeted rehabilitation focuses on strengthening the intrinsic foot muscles, particularly the abductor digiti minimi, which can become atrophied due to chronic denervation. Furthermore, stretching exercises for the Achilles tendon and calf muscles help to reduce the tension that can be transmitted through the foot’s soft tissues, potentially easing pressure on the ICN. Specific nerve gliding exercises are also incorporated to encourage the nerve to move freely within its fascial canal, aiming to break down minor adhesions.
When initial conservative measures fail to provide sufficient or long-lasting relief, which may take several months, the treatment strategy escalates to include targeted injection therapies. The traditional approach involves the use of corticosteroid injections mixed with a local anesthetic, delivered under ultrasound guidance to maximize accuracy and minimize risk. The corticosteroid reduces local inflammation and edema, thereby temporarily decreasing the mechanical compression on the nerve. While effective for immediate pain relief, repeat steroid injections are cautioned against due to the potential for local tissue toxicity and atrophy, especially concerning the surrounding fat pad and ligaments.
More recently, regenerative and minimally invasive therapies have gained prominence, particularly nerve hydrodissection. This technique, typically performed under ultrasound guidance, involves injecting a fluid (such as a 5% dextrose solution, saline, or anesthetic) into the space surrounding the entrapped nerve. The hydrostatic pressure of the injected fluid physically separates the nerve from the constricting surrounding fascia, such as the deep fascia of the abductor hallucis muscle. This process aims to free the nerve from scar tissue and adhesions, effectively decompressing it and improving its gliding capacity. Regenerative medicine options, such as Platelet-Rich Plasma (PRP) used for hydrodissection, are also being explored for their potential to provide growth factors that promote nerve healing and reduce chronic inflammation.
In cases where conservative management, including targeted injections, fails to alleviate symptoms—a condition often termed recalcitrant heel pain—surgical intervention becomes the final and definitive treatment option. The goal of surgery is precise neurolysis, or the surgical decompression of the inferior calcaneal nerve. This procedure is typically indicated when symptoms have persisted for six months or more despite rigorous non-operative care, or when magnetic resonance imaging (MRI) shows clear evidence of denervation atrophy in the abductor digiti minimi muscle, indicating chronic nerve damage.
Surgical decompression can be performed through traditional open techniques or, increasingly, through minimally invasive or endoscopic methods. The open approach involves a small incision on the medial aspect of the heel, allowing the surgeon to carefully dissect and release the tight fascial bands that are entrapping the ICN. Crucially, the deep fascia of the abductor hallucis muscle and any other constricting structures are incised. Given the common co-existence of Baxter’s neuropathy with chronic plantar fasciitis, the neurolysis procedure is often performed concurrently with a partial release of the plantar fascia to address all contributing factors to the patient’s chronic pain.
Endoscopic techniques have been developed to reduce incision size, soft tissue disruption, and postoperative recovery time. Utilizing a small arthroscope, the surgeon can visualize the anatomy and perform the necessary decompression of the nerve and release of the fascia through tiny portals. Regardless of the surgical technique employed, the primary objective remains the same: to create adequate space for the ICN, thus relieving pressure and allowing the nerve to recover its normal function.
The long-term success of treatment for Baxter’s neuropathy is heavily dependent on accurate diagnosis and adherence to the structured progression of care. While conservative measures boast good success rates in many cases, persistent symptoms warrant aggressive intervention, whether through advanced regenerative injections or surgical neurolysis. Post-surgical management is crucial, involving a period of controlled weight-bearing followed by comprehensive physical therapy to regain strength and mobility. Although full recovery can take several months, studies on surgical outcomes suggest high patient satisfaction and significant pain reduction, particularly when the nerve release is combined with addressing other biomechanical issues. Ultimately, the successful management of Baxter’s neuropathy lies in recognizing it as a specific nerve entrapment syndrome rather than a simple case of heel inflammation, and treating it with targeted, systematic strategies that respect the delicate nature of the compressed nerve.